---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007664"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:24:04.698024+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# KALA BIO Q1 net loss $8.9M; cash $42.2M; KPI-012 Phase 2b topline data due Q3 2025

## Summary
- Cash and cash equivalents of $42.2M as of March 31, 2025, expected to fund operations into Q1 2026.
- Q1 2025 net loss $8.9M ($1.41 per diluted share) vs $11.8M ($4.20) prior year; operating loss $10.7M.
- G&A $4.6M (down from $5.4M); R&D $6.1M (down from $6.4M). Weighted shares 6.3M vs 2.8M.
- Phase 2b CHASE trial of KPI-012 in PCED continues enrolling; topline data anticipated in Q3 2025.
- Exploring KPI-012 for Limbal Stem Cell Deficiency; preclinical KPI-014 for inherited retinal diseases.

## SEC filing metadata
- accession: 0001558370-25-007664
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837025007664/0001558370-25-007664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837025007664/kala-20250514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007664
- JSON: https://secwatch.observer/filing/0001558370-25-007664.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007664.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.